<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Clinical studies over the last 20 years using more intensive <z:chebi fb="0" ids="35610">cytostatic</z:chebi> regimens show improved results in children and adolescents with aggressive non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and in adult patients specifically with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS: We present a retrospective analysis of the use of the Berlin-Frankfurt-Munster (BFM) regimen for patients older than 15 years from three Norwegian university hospitals during the 1992-99 period </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Survival data for 24 patients 15-69 years old with Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/B-cell <z:hpo ids='HP_0011009'>acute</z:hpo> lymphoblastic <z:mpath ids='MPATH_336'>leukaemia</z:mpath> (<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e>) show an estimated overall five year survival of 70% (75% for Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> only) </plain></SENT>
<SENT sid="3" pm="."><plain>Eight of ten adolescent patients 15-20 years old with other aggressive <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were alive and disease free at last follow-up </plain></SENT>
<SENT sid="4" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> nine patients given the regimen after failure of prior therapy died of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> within six years </plain></SENT>
<SENT sid="5" pm="."><plain>INTERPRETATION: The BFM regimen yields impressive results as the primary treatment of adolescent and adult patients with Burkitt's <z:hpo ids='HP_0002665'>lymphomas</z:hpo>/<z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
</text></document>